Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322048 · ClinicalTrials.gov registry record · Phase 2
DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01322048 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 48 participants.
The verdict
NCT01322048, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI). The primary hypothesis is that adrenergic blockade after severe TBI will be associated with increased ventilator-free days.
Interventions
- DRUG Placebo
- DRUG IV Propranolol and Per Tube Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01322048
The ClinicalTrials.gov registry entry for NCT01322048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01322048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01322048 about?
NCT01322048 is a clinical study titled "DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury". The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI). The primary hypothesis is that adrenergic blockade after severe TBI will be associated...
What is the current status of trial NCT01322048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2011-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01322048?
The interventions under investigation include: Placebo (DRUG), IV Propranolol and Per Tube Clonidine (DRUG).
Who is sponsoring clinical trial NCT01322048?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.